Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Early Breast Cancer × Carboplatin × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 109 Lung Neoplasms 42 Squamous Cell Carcinoma of Head and Neck 24 Triple Negative Breast Neoplasms 22 Ovarian Neoplasms 20 Small Cell Lung Carcinoma 19 Breast Neoplasms 19 Fallopian Tube Neoplasms 16 Endometrial Neoplasms 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Neoplasms 12 Prostatic Neoplasms 11 Neoplasm Metastasis 11 Colorectal Neoplasms 11 Head and Neck Neoplasms 9 Carcinoma, Squamous Cell 9 Carcinoma 9 Uterine Cervical Neoplasms 8 Oropharyngeal Neoplasms 8 Laryngeal Neoplasms 8 Esophageal Neoplasms 8 Urinary Bladder Neoplasms 7 Pancreatic Neoplasms 7 Mouth Neoplasms 7 Carcinoma, Transitional Cell 7 Brain Neoplasms 5 Adenocarcinoma of Lung 5 Stomach Neoplasms 4 Respiratory Tract Neoplasms 4 Recurrence 4

Interventions

pertuzumab 2 Trastuzumab 2 pyrotinib 1 Taxes 1 Surgical Procedures, Operative 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07340398 2026-01-21

TAYLOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting

HER2-positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡